StockWatch: Abivax Survives a Roller Coaster Week

- StockWatch: Abivax Survives a Roller Coaster Week. Abivax’s stock plummeted after analysts from Jefferies, Morgan Stanley, Truist Securities, and Wedbush Securities raised as a safety concern a portion of data showing malignancies in nine patients among the 580 enrolled in the study. Jefferies reacted the strongest among the firms, downgrading Abivax’s stock rating from “Buy” to “Hold” and lowering its 12-month price target on the company’s shares 44%, from $160 to $90. The post StockWatch: Abivax Survives a Roller Coaster Week appeared first on GEN - Genetic Engineering and Biotechnology News .